Bone Abstracts

Alendronate is one of the most popular anti-resorptive drugs and widely used to treat osteoporotic patients in the world. In Japan, alendronate oral jelly (ALN-J) as a new formulation was launched in 2013. Dissolution test and bioequivalence study were performed between ALN-J and alendronate oral weekly tablet (ALN-T), and bioequivalence of both drugs was approved. Dosage and administration of ALN-J is the same as ALN-T. Moreover, ALN-J has special features of easy swallowing ...

Introduction: Minodronate, a new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. Aside from being a highly potent inhibitor of bone resorption, minodronate has been shown to possess antagonistic action against the P2X2/3 receptor, which has an important role in nociceptive transmission. The purpose of this study was to investigate the analgesic effects of once-monthly oral minodronate (MIN50 mg) on low back pain (LBP) associat...

Introduction: Minodronate, a highly potent, new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate the effects of once-monthly oral minodronate on bone turnover markers (BTM) and bone mineral density (BMD) in osteoporotic patients previously using daily or weekly BPs in real clinical practice.Methods: We conducted a prospective multicenter study involving 11 i...

Introduction: Bisphosphonates (BPs) are currently the mainstay of treatment in osteoporosis; however, the complex dosing regimens might interfere with long-term adherence, which provided the rationale to develop BPs with less-frequent dosing schedules. Minodronate (MIN 50 mg), a highly potent new-generation BP, is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate patient preference for, and adherence to, MIN 50 mg i...